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Over a quarter of parous women experience a complication of pregnancy, such as a 
hypertensive disorder of pregnancy (HDP, preeclampsia and gestational 
hypertension), gestational diabetes (GDM), foetal growth restriction (FGR) or 
preterm delivery. There is now substantial evidence that these women are 
approximately twice as likely to go on to develop cardiovascular disease (CVD) 
compared to women with uncomplicated pregnancies.1  
Using data from Nurses’ Health Study II, Stuart and colleagues report associations 
between a history of a first pregnancy complicated by HDP and physician-diagnosed 
hypertension, hypercholesterolemia and type 2 diabetes over the course of three 
decades following pregnancy[ref]. They found that women who had preeclampsia in 
their first pregnancy had a 2.2-fold increased risk of developing hypertension, a 75% 
increased risk of type 2 diabetes and a 31% increased risk of hypercholesterolemia 
compared to women with a normotensive first pregnancy. Equivalent estimates for 
women who had gestational hypertension in their first pregnancy were 2.8, 65% and 
36%, respectively. Results were similar when analyses were not limited to first 
pregnancies.  
Stuart and colleagues were able to account for a wide range of pre-pregnancy risk 
factors including pre-pregnancy body mass index that may confound the relationship 
between HDP and cardiovascular risk factors. However due to the lack of relevant 
data, they were unable to adjust for pre-pregnancy measures of blood pressure, 
cholesterol and/or glucose. Therefore, the nature of the association between HDP 
(and/or other pregnancy complications) and CVD remains to be clarified. Do HDP 
per se contribute to the increased CVD risk; or do HDP simply identify women who 
have ‘failed’ the cardiometabolic stress test of pregnancy due to a pre-existing 
increased propensity for CVD. This question has practical implications. If HDP 
increase CVD risk independently of pre-pregnancy cardiovascular health (by causing 
end organ damage for example) then prevention of such complications has the 
potential to reduce the burden of CVD in women. If, on the other hand, pre-
pregnancy cardiovascular health is key, then prevention efforts should be aimed at 
young women. Establishing the nature of this relationship requires pre-pregnancy 
measures of cardiovascular health in addition to information on pregnancy 
complications and cardiovascular health after pregnancy, but pregnancy and birth 
cohorts typically recruit women who are already pregnant. In theory, Mendelian 
randomization could also be used, but to date there are no known genetic 
instruments for HDP.  
Stuart and colleagues also find that women with a history of HDP developed CVD 
risk factors at an earlier age than women without HDP. This finding is important as it 
suggests that women with a history of HDP could benefit from undergoing 
cardiovascular risk assessment at an earlier age than women without HDP. Recent 
European and American guidelines2, 3 include a woman’s obstetric history in the 
evaluation of CVD risk with a recommendation that “appropriate referral postpartum 
by the obstetrician to a primary care physician or cardiologist should occur so that in 
the years after pregnancy, risk factors can be carefully monitored and controlled.”3 
However, there is a dearth of evidence to inform optimal monitoring and prevention 
protocols. The current study by Stuart and colleagues makes an important 
contribution to fleshing out these recommendations. Additional prospective studies 
with repeat measures of these cardiovascular risk factors are needed to build on the 
present study findings.  
The burden of cardiovascular disease is ….. Pregnancy may provide an opportunity 
to identify and ameliorate this risk. The long time gap between pregnancy and CVD 
events makes this an challenging area for research but Stuart and colleagues’ 
findings strengthen the need to invest in furthering this research agenda in order to 
reduce the burden of CVD in women.   
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